- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02923427
I-gel vs LMA Supreme in Laparoscopic Gynecological Surgery
October 6, 2020 updated by: Sule Ozbilgin, Dokuz Eylul University
Comparison of I-gel and LMA Supreme Without Neuromuscular Blocker in Laparoscopic Gynecological Surgery
To compare the effects of i-gel and Laryngeal mask airway Supreme (LMA-Supreme) on ventilation parameters and surgical view during Trendelenburg Position laparoscopic gynecological surgery in cases administered positive pressure ventilation without the use of neuromuscular agents.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Prospective, randomized and double-blind study, aged from 18 to 65 years undergoing elective laparoscopic gynecological surgery.
The patients are randomly assigned to 2 groups:
- Group 1: i-gel
- Group 2: LMA- Supreme
Procedure:
The investigation protocol contains the following sections:
- Induction of anaesthesia. For preoperative sedation 0.02 mg/kg midazolam IV will be administered. 2 minutes of 0.2 µ/kg/min remifentanil and 6 mg kg st-1 propofol infusion, IV 1-2 mg kg-1 propofol . No muscle relaxant will be used for insertion of the airway device.
- Bispectral index values will be held between 40-60.Bispectral index values will be within this interval by increasing or decreasing propofol infusion by 1 mg/kg after additional bolus dose of propofol (1 mg/kg).
- Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations. All devices are deflated a lubricated prior to use. Once inserted, the cuff is be inflated with a manometer up to 60 cm H20 Data recorded: size of airway device, time an number of attempts.
- Anesthesia maintenance will be ensured by 50% O2/air with 0.1-0.4 µ kg/min-1 remifentanil and 50-150 µ kg/ min-1 (4-10 mg/kg/hr) propofol IV infusion
- Functionality of the gastric drainage channel of the airway device: passage of a 14 G size tube.
- Measurement of airway seal pressure (oropharyngeal leak pressure (OLP): at baseline, and at 2 minutes after airway device insertion (T1), 10 minutes after insufflation (T2), before desufflation (T3), before removal of airway device (T4). The maximum pressure allowed is 40 cm H2O.
- Ventilatory mechanics and parameters and hemodynamic parameters are measured at baseline, and at T1, T2, T3 and T4.
- Perioperative complications: Cough, vomiting, laryngeal spasm, laryngeal Stridor, airway intervention requirements, hypoxia (SpO2 < 92%)
- Removal of the airway device: Presence of blood - 3 level grading (1:no blood; 2: trace amounts of blood; 3: clear amounts of blood). Complications: sore throat ( VAS:10-point scale), dysphonia (yes/no), dysphagia (yes/no).
Study Type
Interventional
Enrollment (Actual)
112
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
İzmir, Turkey, 35340
- Dokuz Eylül University, School of Medicine, Department of Anesthesiology and Reanimation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- American Society of Anesthesiologists classification group I-II
- between 18-65 years
- undergoing elective laparoscopic gynecological surgery
Exclusion Criteria:
- Those with any neck or upper respiratory tract pathology
- Those at risk of gastric content regurgitation/aspiration (previous upper Gastrointestinal system surgery, known hiatus hernia, gastroesophageal reflux, history of peptic ulcers, full stomach, pregnancy)
- Those with low pulmonary compliance or high airway resistance (chronic pulmonary diseases)
- Obese patients (BMI >35)
- Those with throat pain, dysphagia and dysphonia
- Those with possible or previous difficult airway
- Those with operations planned for longer than 4 hours
- Conversion to laparatomy
- Neuromuscular blocking agent used
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Laryngeal mask Supreme
Insertion of the "Laryngeal mask Supreme" and evaluation of its clinical performance
|
Evaluation of clinical performance in terms of Insertion, ventilation and complications
|
|
Experimental: i-gel
Insertion of the "i-gel" and evaluation of its clinical performance
|
Evaluation of clinical performance in terms of Insertion,ventilation and complications
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Airway Seal Pressure Values
Time Frame: At baseline and at 15, 30 and 60 minutes
|
This value is important as it indicates the feasibility of positive pressure ventilation and the degree of airway protection from supracuff soiling.
It is also used in LMA studies as an index of successful placement.Airway pressures of ≈20 cm H2O are typically required in routine practice.
|
At baseline and at 15, 30 and 60 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual Quality
Time Frame: during pneumoperitoneum
|
quality of surgical view will evaluate by the scala.
quality of surgical view will be assessed with points from 1 to 4 by the surgeon blind to the airway device; (1:best, 4: worst).
|
during pneumoperitoneum
|
|
Gastric Tube Insertion
Time Frame: following airway device insertion up to 5 minutes
|
Number of Participants According to Ease of Gastric Tube Insertion.Ease of passage of a gastric tube as: very easy, easy, difficult or very difficult.
|
following airway device insertion up to 5 minutes
|
|
Postoperative Pharyngolaryngeal Morbidity
Time Frame: postoperative first hour and 24th hour
|
Sore throat evaluted by Visual Analogue Scale.
The visual analog scale, also known as the graphic rating scale is a simple, valid and reliable subjective measure.
Scores are ranked on a 10-cm line that stretches between two extremes - "no pain" and "worst pain".
Total range provided"0 (no pain) to 10 (worst pain).
|
postoperative first hour and 24th hour
|
|
Sufficiency of Pneumoperitoneum
Time Frame: baseline
|
Number of Participants with Sufficiency of Pneumoperitoneum.
Sufficiency of pneumoperitoneum for the surgical procedure according to surgeon, described as sufficient or insufficient questionaire.
|
baseline
|
|
Mean Airway Pressure Values
Time Frame: At baseline and at 15, 30 and 60 minutes
|
Mean airway pressure typically refers to the mean pressure applied during positive-pressure mechanical ventilation.
Mean airway pressure correlates with alveolar ventilation, arterial oxygenation, hemodynamic performance, and barotrauma.
|
At baseline and at 15, 30 and 60 minutes
|
|
Dysphonia With Yes/no.
Time Frame: postoperative first hour and 24th hour
|
We evaluated while a patient was talking with us that the patient has dysphonia or not .
|
postoperative first hour and 24th hour
|
|
Disphagia
Time Frame: postoperative first hour and 24th hour
|
We asked the question that you have a pain while you were swallowing, yes or not.
|
postoperative first hour and 24th hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ferim Günenç, MD, Dokuz Eylül University, School of Medicine, Department of Anesthesiology and Reanimation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2015
Primary Completion (Actual)
September 1, 2017
Study Completion (Actual)
November 1, 2017
Study Registration Dates
First Submitted
September 22, 2016
First Submitted That Met QC Criteria
October 3, 2016
First Posted (Estimate)
October 4, 2016
Study Record Updates
Last Update Posted (Actual)
October 27, 2020
Last Update Submitted That Met QC Criteria
October 6, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- 266-SBKAEK
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.